Bortezomib in combination with celecoxib in patients with advanced solid tumors: A phase I trial

John Hayslip, Uzair Chaudhary, Mark Green, Mario Meyer, Steven Dunder, Carol Sherman, Shanta Salzer, Andrew Kraft, Alberto J. Montero

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Background: COX-2 inhibitors, such as celecoxib, and ubiquitin-proteasome pathway inhibitors, such as bortezomib, can down-regulate NF-κB, a transcription factor implicated in tumor growth. The objective of this study was to determine the maximum tolerated dose and dose-limiting toxicities of bortezomib in combination with celecoxib in patients with advanced solid tumors. Methods: Patients received escalating doses of bortezomib either on a weekly schedule (days 1, 8, 15, 22, and 29 repeated every 42 days) or on a twice-weekly administration schedule (days 1, 4, 8, and 11 repeated every 21 days), in combination with escalating doses of celecoxib twice daily throughout the study period from 200 mg to 400 mg twice daily. Results: No dose-limiting toxicity was observed during the study period. Two patients had stable disease lasting for four and five months each, and sixteen patients developed progressive disease. Conclusion: The combination of bortezomib and celecoxib was well tolerated, without dose limiting toxicities observed throughout the dosing ranges tested, and will be studied further at the highest dose levels investigated.

Original languageEnglish (US)
Article number221
JournalBMC Cancer
Volume7
DOIs
StatePublished - Dec 3 2007
Externally publishedYes

ASJC Scopus subject areas

  • Genetics
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Bortezomib in combination with celecoxib in patients with advanced solid tumors: A phase I trial'. Together they form a unique fingerprint.

  • Cite this

    Hayslip, J., Chaudhary, U., Green, M., Meyer, M., Dunder, S., Sherman, C., Salzer, S., Kraft, A., & Montero, A. J. (2007). Bortezomib in combination with celecoxib in patients with advanced solid tumors: A phase I trial. BMC Cancer, 7, [221]. https://doi.org/10.1186/1471-2407-7-221